Literature DB >> 11743940

The changing roles and targets for animal models of schizophrenia.

C D Kilts1.   

Abstract

Unlike disorders of other fields of medicine (eg., diabetes, heart disease), schizophrenia has been only marginally impacted by the study of animal models. This gap reflects the incomplete understanding of the causes and mechanisms of schizophrenia and the resulting lack of defined targets for model development. However, prior attempts at modeling in animals the complex symptoms of schizophrenia have given way to more promising component models. This review will address the evolving field of animal models of schizophrenia with a focus on models of errors in neurotransmission, and of psychophysiological deficits, with a concluding discussion of the present and future promise of genetic-based models. Evolving models based on the long-held conceptualization of schizophrenia as being based on errors in neurotransmission are discussed as regards the integration of newer findings implicating alterations in dopamine, glutamate and neurotensin function in the pathophysiology and pharmacotherapy of schizophrenia. The case for the more recent conceptualization of schizophrenia as a core deficit in information processing and stimulus filtering is discussed. Animal behavioral paradigms that model psychophysiologic constructs of stimulus processing deficits related to schizophrenia include prepulse inhibition (PPI), a model of sensorimotor gating, or latent inhibition (LI), a model of salience learning. These models represent both better supported associations with schizophrenia and more productive targets and are providing important new information regarding the psychopharmacology of schizophrenia. Genetic models of schizophrenia are based on the demonstrated heritability of the disorder and more recent pharmacogenetic findings for antipsychotic medications. Genetic-based animal models use behavioral or molecular genetic techniques to manipulate behaviors related to schizophrenia by altering the frequencies of related genes. The future development of increasingly informative animal models of schizophrenia will be dependent on a more complete understanding of schizophrenia, an integration of findings across animal models and refinements in the criteria used to assess model "validity" that better reflect the changing nature and roles of animal models of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11743940     DOI: 10.1016/s0006-3223(01)01286-0

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  16 in total

Review 1.  Ethical issues in the use of animals in biomedical and psychopharmocological research.

Authors:  John P Gluck; Jordan Bell
Journal:  Psychopharmacology (Berl)       Date:  2003-05-28       Impact factor: 4.530

Review 2.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 3.  Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

Authors:  Gary Remington
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

4.  Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.

Authors:  Segev Barak; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

5.  Coantagonism of glutamate receptors and nicotinic acetylcholinergic receptors disrupts fear conditioning and latent inhibition of fear conditioning.

Authors:  Thomas J Gould; Michael C Lewis
Journal:  Learn Mem       Date:  2005 Jul-Aug       Impact factor: 2.460

Review 6.  How antipsychotics work-from receptors to reality.

Authors:  Shitij Kapur; Ofer Agid; Romina Mizrahi; Ming Li
Journal:  NeuroRx       Date:  2006-01

7.  Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine.

Authors:  Chen Zhang; Ming Li
Journal:  Behav Pharmacol       Date:  2012-02       Impact factor: 2.293

8.  Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia.

Authors:  Kara Kittelberger; Elizabeth E Hur; Saba Sazegar; Vidya Keshavan; Bernat Kocsis
Journal:  Brain Struct Funct       Date:  2011-10-07       Impact factor: 3.270

9.  Functional networks underlying latent inhibition learning in the mouse brain.

Authors:  Frank Puga; Douglas W Barrett; Christel C Bastida; F Gonzalez-Lima
Journal:  Neuroimage       Date:  2007-07-18       Impact factor: 6.556

Review 10.  Glutamatergic abnormalities of the thalamus in schizophrenia: a systematic review.

Authors:  L Watis; S H Chen; H C Chua; S A Chong; K Sim
Journal:  J Neural Transm (Vienna)       Date:  2008-02-26       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.